Avrobioincis A Biotechnology Company Based In Cambridgemassachusettswith Operations In Torontoontariofounded In 2015The Company Focuses On Developing Gene Therapies For Rare Genetic Diseases Caused By Single Gene Mutationsavrobio Aims To Provide Personalized Gene Therapy By Introducing Functional Copies Of Affected Genes Into Patientsown Hematopoietic Stem Cellspromoting Long Lasting Therapeutic Effects The Company Specializes In Lentiviral Based Gene Therapies And Ex Vivo Gene Modification Techniqueskey Therapeutic Candidates Include Avr Rd 01 For Fabry Diseaseavr Rd 02 For Cystinosisavr Rd 03 For Gaucher Diseaseand Avr Rd 04 For Pompe Diseaseavrobio Is Actively Conducting Clinical Trials To Evaluate The Safety And Efficacy Of Its Therapieswith Positive Results Reported For Avr Rd 01 In Treating Fabry Diseasein January 2024Avrobio Announced A Reverse Merger With Tectonic Therapeuticmarking A New Chapter In Its Development
